CSIMarket
 


Amgen Inc   (AMGN)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare

Amgen Inc 's

Competitiveness


 

AMGN Sales vs. its Competitors Q2 2021



Comparing the results to its competitors, Amgen Inc reported Total Revenue decrease in the 2 quarter 2021 year on year by 0 %, despite revenue increase by most of its competitors of 26.92 %, recorded in the same quarter.

List of AMGN Competitors

With net margin of 0 % company reported lower profitability than its competitors.

More on AMGN Margin Comparisons



Revenue Growth Comparisons




Net Income Comparison


Amgen Inc Net Income in 2 quarter 2021 declined year on year by -74.27 %, despite income growth by most of its competitors

<<  More on AMGN Income Comparisons


Amgen Inc 's Comment on Competitors and Industry Peers


Certain of our marketed products face — and our product candidates, if approved, are also expected to face — substantial competition. Our products’ competitive positions among other biological and pharmaceutical products may be based on, among other things, safety, efficacy, reliability, availability, patient convenience/delivery devices, price, reimbursement, timing of market entry and patent position and expirations.

Certain of the existing patents on our principal products have recently expired or will expire over the next few years, and we expect to face increasing competition thereafter, including from biosimilars. A biosimilar is another version of a biological product for which marketing approval is sought or has been obtained based on a demonstration that it is “biosimilar” to the original reference product. See Government Regulation. We may also compete against biosimilar or generic versions of our competitors’ products. In the EU, we are facing increasing competition from biosimilars. In the United States after patent expiration, we expect to face greater competition than today, including from manufacturers with biosimilars approved in Europe, which may seek to obtain U.S. approval.

Some of our products compete with each other. For example, Aranesp® and EPOGEN® compete in the United States, primarily in the dialysis setting. Neulasta® competes with NEUPOGEN®, as Neulasta® is administered as a single dose per chemotherapy cycle while NEUPOGEN® requires more frequent dosing. NEUPOGEN® sales have been adversely impacted by conversion to Neulasta®, which we believe is substantially complete.
The introduction of new products, the development of new processes or technologies by competitors or the emergence of new information about existing products may result in increased competition for our marketed products, even for those protected by patents, or in a reduction of the price that we receive from selling our products. In addition, the development of new treatment options or standards of care may reduce the use of our products or may limit the utility and application of ongoing clinical trials for our product candidates. The following table reflects our significant competitors and is not exhaustive.





*Market share calculated with total revenue.


AMGN's vs. Competition, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Amgen Inc 32,341 123,039 5,746 17,900
Abbvie Inc 53,729 190,156 6,675 26,000
Abbott Laboratories 40,233 223,030 6,376 77,000
Actavis Plc 10,573 3,808 -751 19,200
Allergan plc 16,096 64,063 -2,479 10,500
Bristol Myers Squibb Co 44,384 135,197 -5,059 25,000
Celgene Corp 16,982 78,961 1,834 6,012
Cephalon, Inc. 0 0 0 0
Johnson and Johnson 89,190 439,104 17,767 126,500
Eli Lilly And Company 26,726 210,921 6,071 39,135
MEDIMMUNE, INC. 0 0 0 0
Merck and Co Inc 48,547 186,438 5,585 70,000
Pfizer Inc 57,374 249,491 13,282 78,300
SCHERING-PLOUGH CORPORATION 0 0 0 0
Watson Pharmaceuticals Inc 0 0 0 0
Wyeth 0 0 0 0
Alexion Pharmaceuticals Inc 6,262 40,625 535 2,273
Biogen Inc 11,698 43,786 2,492 7,550
Covidien Plc 10,880 0 1,605 39,500
Mylan N v 16,861 8,208 266 25,000
Hospira Inc 6,921 0 -8 0
SUBTOTAL 488,797 1,996,830 59,936 569,870


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

AIT's Profile

Stock Price

AIT's Financials

Business Description

Fundamentals

Charts & Quotes

AIT's News

Suppliers

AIT's Competitors

Customers & Markets

Economic Indicators

AIT's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071